Evaluation of utilised doses of Heart Failure (HF) medications between genders and its association with clinical status among Heart Failure (HF) patients at hospital Serdang
Keywords:
heart failure, utilised doses, genders, clinical statusAbstract
Objective This study aimed to evaluate the utilised doses of HF medications between genders among HF patients in local setting. Methods This study was conducted as retrospective study involving data collection from medical records of patients with documented HF in Hospital Serdang, Selangor. A total of 131 patients (74 males versus 57 females) were conveniently recruited from patients undergoing follow-ups at cardiology outpatient clinic, Hospital Serdang, Selangor with matched age, different ethnics, baseline and current EF and comorbidities. Utilised doses of HF medications were categorised as percentage of recommended doses or usual daily doses, which were 0%, <50%, ≥50% and ≥100%.Results No significant difference was observed in utilised doses of HF medications between genders in study population which proved that the utilised doses of HF medications were not influenced by gender differences. However, Malay and Indian were found to utilise higher MRA doses compared to Chinese and indigenous people (P < 0.05). This study also found that baseline (r = -0.386; P < 0.001) and current (r = -0.265; P < 0.01) ejection fraction were weakly and inversely correlated with MRA utilised doses.
Downloads
References
Hunt SA. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. J Am Coll Cardiol [Internet]. 2005;46(6):e1–82.
Khatibzadeh S, Farzadfar F, Oliver J, Ezzati M, Moran A. Worldwide risk factors for heart failure: a systematic review and pooled analysis. Int J Cardiol. 2013;168(2):1186–94.
Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, et al. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet. 2019;394(10205):1254–63.
Whitley HP, Lindsey W. Sex-based differences in drug activity. Am Fam Physician. 2009;80(11):1254–8.
Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32.
Lam CSP. Heart failure in Southeast Asia: facts and numbers. ESC Hear Fail [Internet]. 2015;2(2):46–9.
MacDonald MR, Tay WT, Teng THK, Anand I, Ling LH, Yap J, et al. Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN-HF Registry. J Am Heart Assoc. 2020;9(1):1–15.
Chong AY, Rajaratnam R, Hussein NR, Lip GYH. Heart failure in a multiethnic population in Kuala Lumpur, Malaysia. Eur J Heart Fail. 2003;5(4):569–74.
Soenarta AA, Buranakitjaroen P, Chia YC, Chen CH, Nailes J, Hoshide S, et al. An overview of hypertension and cardiac involvement in Asia: Focus on heart failure. J Clin Hypertens. 2020;22(3):423–30.
Aggarwal A, Srivastava S, Velmurugan M. Newer perspectives of coronary artery disease in young. World J Cardiol. 2016;8(12):728.
Lam CSP, Teng THK, Tay WT, Anand I, Zhang S, Shimizu W, et al. Regional and ethnic differences among patients with heart failure in Asia: The Asian sudden cardiac death in heart failure registry. Eur Heart J. 2016;37(41):3141–53.
Bosch L, Assmann P, de Grauw WJC, Schalk BWM, Biermans MCJ. Heart failure in primary care: prevalence related to age and comorbidity. Prim Health Care Res Dev. 2019;20:e79.
Sato N. Epidemiology of Heart Failure in Asia. Heart Fail Clin. 2015;11(4):573–9.
Tai C, Gan T, Zou L, Sun Y, Zhang Y, Chen W, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: A meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2017;17(1):1–12.
Dézsi CA. The different therapeutic choices with ARBs. Which one to give? When? Why? Am J Cardiovasc Drugs. 2016;16(4):255–66.
Fröhlich H, Torres L, Täger T, Schellberg D, Corletto A, Kazmi S, et al. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clin Res Cardiol. 2017;106(9):711–21.
Choi KH, Lee GY, Choi JO, Jeon ES, Lee HY, Lee SE, et al. The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction. Korean J Intern Med. 2019;34(5):1030–9.
Chatterjee S, Moeller C, Shah N, Bolorunduro O, Lichstein E, Moskovits N, et al. Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med [Internet]. 2012;125(8):817–25.
Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int [Internet]. 2019;96(2):302–19. Available from:
Casu G, Merella P. Diuretic therapy in heart failure - Current approaches. Eur Cardiol Rev . 2015;10(1):42–7.
Pellicori P, Kaur K, Clark AL. Fluid Management in Patients with Chronic Heart Failure. Card Fail Rev. 2015;1(2):90–5.
Teng TK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry : a cohort study. Lancet Glob Heal [Internet]. 2018;6(9):e1008–18. Available from:
Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, et al. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: Individual patient data meta-analysis. BMJ. 2016;353.
Paolillo S, Mapelli M, Bonomi A, Corrà U, Piepoli M, Veglia F, et al. Prognostic role of β-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database. Eur J Heart Fail. 2017;19(7):904–14.
Bloch MJ, Basile JN. Spironolactone is more effective than eplerenone at lowering blood pressure in patients with primary aldosteronism. J Clin Hypertens. 2011;13(8):629–31.
Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlström U, et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2018;20(9):1326–34.
Pavlusova M, Miklik R, Spacek R, Benesova K, Zeman K, Cohen-Solal A, et al. Increased dose of diuretics correlates with severity of heart failure and renal dysfunction and does not lead to reduction of mortality and rehospitalizations due to acute decompensation of heart failure; data from AHEAD registry. Czech Soc Cardiol. 2018;60(3):e215–23.
Kohn JC, Lampi MC, Reinhart-King CA. Age-related vascular stiffening: Causes and consequences. Front Genet. 2015;6(MAR):1–17.
Veenis JF, Brunner-La Rocca HP, Linssen GCM, Geerlings PR, Van Gent MWF, Aksoy I, et al. Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction. Eur J Prev Cardiol. 2019;26(13):1399–407.
Amplavanar NT, Gurpreet K, Salmiah MS, Odhayakumar N. Prevalence of cardiovascular disease risk factors among attendees of the batu 9, Cheras health centre, Selangor, Malaysia. Med J Malaysia. 2010;65(3):166–72.
Iqbal SP, Ramadas A, Fatt QK, Shin HL, Onn WY, Kadir KA. Relationship of sociodemographic and lifestyle factors and diet habits with metabolic syndrome (MetS) among three ethnic groups of the Malaysian population. PLoS One [Internet]. 2020;15(3):1–16.
Mansor M, Harun NZ. Health Issues and Awareness, and the Significant of Green Space for Health Promotion in Malaysia. Procedia - Soc Behav Sci [Internet]. 2014;153:209–20. Available from:
Kapelios CJ, Murrow JR, Nührenberg TG, Montoro Lopez MN. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev. 2019;24(3):367–77.
Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? J Am Coll Cardiol [Internet]. 2018;71(13):1474–82.
Elgendy IY, Mahtta D, Pepine CJ. Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. Circ Res. 2019;124(11):1520–35.
Cooper LB, Lippmann SJ, Greiner MA, Sharma A, Kelly JP, Fonarow GC, et al. Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease. J Am Heart Assoc. 2017;6(12).
Löfman I, Szummer K, Olsson H, Carrero JJ, Lund LH, Jernberg T. Association between mineralocorticoid receptor antagonist use and outcome in myocardial infarction patients with heart failure. J Am Heart Assoc. 2018;7(14).
Neefs J, van den Berg NWE, Krul SPJ, Boekholdt SM, de Groot JR. Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial. Am J Cardiovasc Drugs [Internet]. 2020;20(1):73–80.
Kimura M, Ogawa H, Wakeyama T, Takaki A, Iwami T, Hadano Y, et al. Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure. J Cardiol [Internet]. 2011;57(2):208–14.
Hinder M, Yi BA, Langenickel TH. Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials? Clin Pharmacol Ther. 2018;103(5):802–14.
Bolam H, Morton G, Kalra PR. Drug therapies in chronic heart failure: A focus on reduced ejection fraction. Clin Med J R Coll Physicians London. 2018;18(2):138–45.
Bratsos S. Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials. Cureus. 2019;11(1):1–8.
Cleland JGF, Bunting K V., Flather MD, Altman DG, Holmes J, Coats AJS, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39(1):26–35.
Zannad F, McMurray JJV, Krum H, Veldhuisen DJ van, Swedberg K, Shi H, et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med. 2011;364(1):11–21.
Vizzardi E, Regazzoni V, Caretta G, Gavazzoni M, Sciatti E, Bonadei I, et al. Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives. IJC Hear Vessel [Internet]. 2014;3:6–14.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
